NGS – a weapon in molecular pathology?
Next generation sequencing has revolutionised cancer management, but has also raised some issues that have yet to be addressed
Next generation sequencing has revolutionised cancer management, but has also raised some issues that have yet to be addressed
New recommendations of the MDICT Taskforce highlight the need to rethink how research studies are conducted and of multi-stakeholder collaboration
Among all the stakeholders involved, oncology societies can play a pivotal role to facilitate efficient clinical investigations
The 2023 ESMO TAT Honorary Awardee Prof. Susan E. Bates gives an overview of the lasting challenges and unfulfilled potential of these therapies
Integrated, comprehensive databases may help to close the gap in cancer care between high- and low-/lower-middle-income countries
While some challenges associated with rare cancers are similar in Europe and Asia, resources and differing epidemiology need to be considered when coming up with solutions
Results from a pilot study show that work–family balance is the biggest challenge to career progression for young women
Many studies presented at ESMO Congress 2022 show the potential of artificial intelligence to enhance personalised oncology
Despite the promises shown by some innovative technologies in the studies presented, they will not replace existing diagnostic modalities soon
AI technology is being tested across tumour types and with different purposes, with an emerging trend for adding value to whole slide image analyses for HER2 status
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.